Key result
Single-cell and spatial omics reveal plaque immune cell heterogeneity, highlighting novel cardiovascular therapeutic targets.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In contrast to the use of low-dose colchicine in chronic atherosclerosis, its use in the setting of acute myocardial infarction and unstable angina remains uncertain, justifying a more limited Class 2B recommendation in the new American College of Cardiology/American Heart Association guidelines for acute coronary syndromes.”
Immune heterogeneity mapping offers no change to current atherosclerosis management; leaves open whether identified subsets represent actionable targets pending functional validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Paul M. Ridker (2025) conducted a review in Atherosclerosis. Single-cell and spatial transcriptomics was evaluated. Single-cell and spatial omics technologies have revealed extensive macrophage and T-cell heterogeneity in atherosclerotic plaques, identifying novel immune targets for cardiovascular therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: